

AUTHOR AND EDITOR CONFLICTS OF INTEREST

Maiken Calving Arendruo (coauthor on chapter 135) received research grants/contract work (monies paid to the Statens Serum Institut) from Amplyx, Basilea, Cidara, F2G, Gilead, Novabiotics, Scynexis, and T2 Biosystems and speaker honoraria (personal fee) from Astellas, Gilead, Novartis, MSD, and Seges. Dr. Calving-Arendrup is the current chairman of the EUCAST antifungal susceptibility testing subcommittee.

N. Esther Babady (Section Editor; coauthor on chapters 84 and 89) receives research grants from GenMark Diagnostics, Copan Diagnostics, and Seres Therapeutics. Dr. Babady serves on the Scientific Advisory Committees for Agen Biosciences and BioRad and on the Clinical Advisory Committee for Arc Bio Inc.

Matthew J. Binnicker (Section Editor; coauthor on chapters 83 and 84) is an advisory board member for Luimnex/DiaSorin molecular and Mammoth Biosciences and receives speaking honoraria from Quidel, Abbott, Roche and Seegene.

Richard S. Bradbury (coauthor on chapters 147 and 154) is a coauthor on the following patent (assigned to the Centers for Disease Control and Prevention): Eldin Talundzic, Richard S. Bradbury, Christian Olsen, Briana Flaherty. World Intellectual Property Organization (WIPO) Patent WO2019060840. Removing Interfering Host Nucleic Acids for Molecular Parasite Detection; granted 28 March 2019.

Patricia A. Bradford (coauthor on chapter 72) is an independent microbiology consultant whose clients include Acrum, Allegra, Boston Pharma, Botanix, Bugworks, CarbX, Cipla, Debiopharm, Entasis, Fedora, Sinovent, Vivli, Zai Labs and owns stock in Pfizer. MC is an employee of JMI Laboratories which was contracted to perform services in 2020 for Affinity Biosensors, Allergan, Amicrobe, Inc., Amplyx Pharma, Artugen Therapeutics USA, Inc., Astellas, Basilea, Beth Israel Deaconess Medical Center, BIDMC, BioMérieux, Inc., BioVersys Ag, Bugworks, Cidara, Cipla, Contrafect, Cormedix, Crestone, Inc., Curza, CXC7, Entasis, Fedora Pharmaceutical, Fimbrion Therapeutics, Fox Chase, GlaxoSmithKline, Guardian Therapeutics, Hardy Diagnostics, IHMA, Janssen Research & Development, Johnson & Johnson, Kaleido Biosciences, KBP Biosciences, Luminex, Matrifax, Mayo Clinic, Medpace, Meiji

Seika Pharma Co., Ltd., Melinta, Menarini, Merck, Meridian Bioscience Inc., Micromyx, MicuRx, N8 Medical, Nabriva, National Institutes of Health, National University of Singapore, North Bristol NHS Trust, Novome Biotechnologies, Paratek, Pfizer, Prokaryotics Inc., QPEX Biopharma, Rhode Island Hospital, RIHML, Roche, Roivant, Salvat, Scynexis, SeLux Diagnostics, Shionogi, Specific Diagnostics, Spero, SuperTrans Medical LT, T2 Biosystems, The University of Queensland, Thermo Fisher Scientific, Tufts Medical Center, Universite de Sherbrooke, University of Iowa, University of Iowa Hospitals and Clinics, University of Wisconsin, UNT System College of Pharmacy, URM, UT Southwestern, VenatoRx, Viosera Therapeutics, and Wayne State University.

Sharon C.A. Chen (coauthor on chapter 123) has received educational grants from F2G Ltd. and MSD Australia.

Marc R. Couturier (Section Editor; author on chapter 60; coauthor on chapter 144) receives household income from BioMérieux. and owns stock in BioMérieux. Dr. Couturier also serves on the advisory board for Seegene and is a consultant for BioMérieux.

Christopher D. Doern (coauthor on chapter 7) is on the Scientific Advisory Board for Quidel.

Alexander L. Greninger (coauthor on chapters 101, 102, and 105) reports contract testing from Abbott, Cepheid, Novavax, Pfizer, Janssen and Hologic and research support from Gilead and Merck.

Amanda T. Harrington (coauthor on chapter 5) receives grant funding and honoraria for presentations from BioFire Diagnostics.

Albert Heim (coauthor on chapter 107) receives an honorarium for workshops and seminars presented by Hologic Inc.

Hans H. Hirsch (coauthor on chapter 109) serves as a consultant for Molecular Probes, Roches Diagnostics, and Vera Therapeutics and is a biotest speakers for Gilead.

Nathan A. Ledebor (Section Editor; coauthor on chapters 37, 38, and 39) serves as a consultant/Scientific Advisory Board member for Shionogi, Affinity Biosciences/Life Scale Technologies, Cytovale, ThermoFisher Scientific, Luminex, GeneCapture, Inflammatrix, Copan Diagnostics, Lucira, 3iDx, and Specific Technologies/BioMérieux. Dr. Ledebor is also a board member for CosmosID.

James S. Lewis (coauthor on chapter 71) is a consultant for Merck, Cidara, and Selux Diagnostics.

Blaine A. Mathison (coauthor on chapters 136 and 144; author on chapter 152) has received research reagents from Apacor and Techcye.

Erin McElvania (coauthor on chapter 7) is a speaker for BD Scientific.

Robin Patel (Volume Editor) reports grants from ContraFect, TenNor Therapeutics Limited, and BioFire. Dr. Patel is a consultant to PhAST, Torus Biosystems, Day Zero Diagnostics, Mammoth Biosciences, and HealthTrackRx; monies are paid to Mayo Clinic. Mayo Clinic and Dr. Patel have a relationship with Pathogenomix. Dr. Patel has research supported by Adaptive Phage Therapeutics. Mayo Clinic has a royalty-bearing know-how agreement and equity in Adaptive Phage Therapeutics. Dr. Patel is also a consultant to Netflix, Abbott Laboratories, and CARB-X. In addition, Dr. Patel has a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued. Dr. Patel receives honoraria from the NBME, Up-to-Date and the Infectious Diseases Board Review Course.

Jean B. Patel (Section Editor, coauthor on chapter 75) is an employee of Beckman Coulter Diagnostics and is a shareholder of Danaher stock.

Benjamin A. Pinsky (Section Editor, author on chapter 116; coauthor on chapters 82, 84, and 93) has received research funding from Abbott, Agilent, Altona Diagnostics, Gentegra, Hologic, Kryptos Biotechnologies, Pathogen Dx, and Vela Diagnostics. MesoScale Discovery has provided reagents and instruments. He receives royalties from Globavir and BioRad.

Bobbi S. Pritt (Volume Editor; chapter 140; coauthor chapter 68) serves on the Board of Governors for the College of American Pathologists (CAP) and receives royalties from the CAP Press.

Justin D. Radolf (coauthor on chapter 63) has received royalties for recombinant T. Pallidum proteins used for serological diagnostics.

Sandra S. Richer (coauthor on chapter 75) is an employee of BioMérieux.

Robert W. Shafer (coauthor on chapter 115) has served on advisory boards for Gilead Sciences and GlaxoSmithKline.

Patricia J. Simner (Section Editor; coauthor on chapter 76) reports research contracts from BD Diagnostics, OpGen Inc., Affinity Biosensors, Qiagen Sciences Inc., and T2 Diagnostics. Dr. Simner serves on the speaker's bureau for GenMark X, BD Diagnostics, and OpGen Inc. In addition, Dr. Simner has research collaborations with Ares Genetics, CosmosID, IDbyDNA, and Illumina and consults for OpGen Inc., BD Diagnostics, Shionogi Inc., Gene Capture, Qiagen Sciences, and Entasis.

Neeraj K. Surana (coauthor on chapter 17) holds stock in Pfizer and serves as a consultant to MaaT Pharma.

Eldin Talundzic (coauthor on chapter 154) is a coauthor on the following patent (assigned to the Centers for Disease Control and Prevention): Eldin Talundzic, Richard S Bradbury, Christian Olsen, Briana Flaherty. World Intellectual Property Organization (WIPO) Patent WO2019060840. Removing Interfering Host Nucleic Acids for Molecular Parasite Detection; granted 28 March 2019.

Yi-Wei Tang (Section Editor; coauthor on chapters 84 and 112) is an employee of Danaher/Cepheid.

Shawn Vasoo (coauthor on chapter 3) has received research support in-kind from BioMérieux (BioFire) and Rosco Diagnostica.

Nathan P. Wiederhold (coauthor on chapters 117 and 124) has received research support (monies paid to the University of Texas Health Science Center at San Antonio) from Astellas, Cepheid, Covance, F2G, and Sfunga, and has served on an advisory board for Mayne Pharma.

Sean X. Zhang (Section Editor; coauthor on chapter 124) has received industry research funds and consultation fees from T2 Biosystems, KARIUS, Applied BioCode, Pearl Diagnostics, IMMY Diagnostics, Scanogen Inc., and Vela Diagnostics.

Barbara A. Zimmer (coauthor on chapter 73) is an employee of Beckman Coulter Microbiology.